// App-Quantinova.ai

: The use of five-alpha reductase inhibitors and their association with reclassification and pathologic outcomes in the Canary Prostate Active Surveillance Study (PASS).

Researchers

Presenter

  • James T Kearns

Principal Investigators

  • Anna V Faino

  • Lisa F Newcomb

  • James D. Brooks

  • Peter Carroll

  • Atreya Dash

  • William J Ellis

  • Michael Fabrizio

  • Martin Gleave

  • Todd Matthew Morgan

  • Peter S Nelson

  • Ian Murchie Thompson

  • Andrew Wagner

  • Yingye Zheng

  • Daniel W. Lin

Medical Centers

  • University of Washington, Seattle, WA

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA

  • Department of Medicine, Stanford University, Stanford, CA

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • University of Washington, Seattle, WA

  • Eastern Virginia Medical School, Norfolk, VA

  • Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

  • University of Michigan, Ann Arbor, MI

  • University of Texas Health Science Center San Antonio, San Antonio, TX

  • Beth Israel Deaconess Medical Center, Boston, MA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved